Alnylam Pharma (ALNY) Tops Q2 EPS by 30c
Tweet
Share
E-mail
Get Alerts ALNY Hot Sheet
Price: $259.85 -2.35%
EPS Growth %: -39.0%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
VIVO, BIOX, PMCB, More
EPS Growth %: -39.0%
Financial Fact:
Unrealized (loss) gain on marketable securities: -18.33M
Today's EPS Names:
VIVO, BIOX, PMCB, More
Join SI Premium – FREE
Alnylam Pharma (NASDAQ: ALNY) reported Q2 EPS of ($1.30), $0.30 better than the analyst estimate of ($1.60). Revenue for the quarter came in at $220.1 million versus the consensus estimate of $193.18 million.
For earnings history and earnings-related data on Alnylam Pharma (ALNY) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Activist investor presses Xerox to review financial services arm - Bloomberg
- After an 18% summer selloff in chip stocks, Citi asks what comes next
- HSBC explains why risk assets continue to ignore every negative catalyst
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
